Efficacy and Safety of 4-Weekly Docetaxel for Castration-Resistant Prostate Cancer

Takuya Yamashita, Masaki Shiota, Asako Machidori, Satoshi Kobayashi, Takashi Matsumoto, Keisuke Monji, Eiji Kashiwagi, Ario Takeuchi, Ryosuke Takahashi, Junichi Inokuchi, Ken ichiro Shiga, Akira Yokomizo, Masatoshi Eto

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


We investigated the efficacy and safety profiles of 4-weekly docetaxel for castration-resistant prostate cancer. Patients treated with ≥2 courses of docetaxel chemotherapy (median, 70 mg/m2) between 2008 and 2018 were included. Among 125 Japanese men, 40 (32.0%) and 85 (68.0%) were treated with 3-weekly and 4-weekly regimens, respectively. In the 4-weekly regimen, the risks of progression, treatment failure, and any-cause mortality were comparable to those in the 3-weekly regimen. The incidences of severe adverse events were also similar between the 3-weekly and 4-weekly regimens. These data suggest that the 4-weekly regimen may be an acceptable option for selected patients.

Original languageEnglish
Pages (from-to)251-256
Number of pages6
JournalCancer Investigation
Issue number3
Publication statusPublished - 2021

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'Efficacy and Safety of 4-Weekly Docetaxel for Castration-Resistant Prostate Cancer'. Together they form a unique fingerprint.

Cite this